Title
68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
A Phase II, Open-label Study to Assess Safety and Clinical Utility of 68Ga-THP-PSMA PET/CT in Patients With High Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment (PRONOUNCED Study)
Phase
Phase 2Lead Sponsor
Theragnostics LtdStudy Type
InterventionalStatus
Completed Results PostedIndication/Condition
Prostate CancerIntervention/Treatment
Gallium-68 THP-PSMAStudy Participants
49This will be an open-labelled, single centre study in the UK. The study group will include 60 patients with three groups of patients being studied. Group A will consist of 20 patients who have been newly diagnosed with primary high risk prostate cancer and are scheduled for radical prostatectomy surgery. Group B will consist of 20 patients with a diagnosis of BCR with previous radical prostatectomy, and are being considered for radical salvage therapy. Group C will consist of 20 patients with a diagnosis of BCR with previous radical radiotherapy (but no surgery), and are being considered for radical salvage therapy.
Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
Single intravenous administration of Gallium-68 THP-PSMA
Inclusion Criteria: Group A: Adenocarcinoma of the prostate gland suitable for radical Tx. Adenocarcinoma of Prostate Gleason score 4+3 and above, or PSA > 20 ng/mL or clinical stage >T2C. Suitable for surgical tx No Hormone Therapy in last 3 months Group B: PCa and a diagnosis of BCR, previously treated with radical prostatectomy, being considered for radical salvage therapy (with curative intent). Original diagnosis of PCa, treated with radical curative therapy at least 3 months before enrolment, and has been diagnosed with BCR based on: Post RP: two consecutive rises in PSA and final PSA >0.lng/ml OR Post RP: three consecutive rises in PSA. This definition is also applicable to subjects with PSA persistence post RP (where the PSA fails to fall to undetectable levels). Post RP: PSA doubling time of ~15 months OR PSA level 0.5 ng/ml. No previous recurrences of PCa. Consideration for radical salvage therapy. Should not have received androgen-deprivation therapy within 3 months of screening. No Hormone Therapy in last 3 months Group C: PCa and a diagnosis of BCR, previously treated with radical radiotherapy, being considered for radical salvage therapy (with curative intent). The subject has had an original diagnosis of PCa and underwent radical curative therapy at least 3 months before enrolment, and has been diagnosed with BCR on the basis of: Increase in PSA level ~2.0 ng/ml above the nadir level after radiotherapy (RT) or brachytherapy, no previous recurrences of BCR. The subject is being considered for radical salvage therapy. Should not have received androgen-deprivation therapy within 3 months of screening. No hormone therapy within the past three months. Exclusion Criteria: Group A: Prior Tx for Prostate Tumours Gleason < 4+3 Hip prostheses eGFR <20 Group B: Hormone Therapy in the last 3 months Hip prostheses eGFR <20 Group C: Hormone Therapy in the last 3 months Hip prostheses eGFR <20
| Event Type | Organ System | Event Term | Group A | Groups B and C | Safety Evaluable Population |
|---|
The impact of 68Ga-THP-PSMA PET/CT on the management of patients with PCa was analysed by measuring the percentage of patients who had a change in management plan as a result of 68Ga-THP-PSMA PET/CT documented after scan, compared with their pre-scan management plan. A change status of 'Yes' was assigned if there was any difference in treatment options between the intended and revised management plans. A change status of 'No' was assigned if the intended and revised management plans remained identical. This endpoint was assessed in the full analysis set, but as a sensitivity analysis, was also assessed in the per protocol population in case there was a difference between the populations. As all 49 patients underwent a technically successful post-baseline scan, the full analysis set and per protocol populations were the same.
Safety was assessed by means of physical examination, vital signs, cardiovascular profile, performance status, laboratory evaluations (haematology, biochemistry, urinalysis and prostate-specific antigen), recording of concurrent illness/therapy and AEs. No dose limiting toxicity was defined in this study.
